Response of estrogen receptor-positive intraabdominal fibromatosis to aromatase inhibitor therapy

Obstet Gynecol. 2003 Nov;102(5 Pt 2):1155-8. doi: 10.1016/s0029-7844(03)00674-4.

Abstract

Background: Intraabdominal fibromatosis is a rare tumor-like lesion of uncertain etiology.

Case: A 49-year-old woman underwent abdominal hysterectomy and bilateral salpingooophorectomy in 1997 to treat uterine leiomyomata and ovarian fibromatosis. Postoperatively, she received estradiol 2 mg daily as hormone replacement therapy (HRT). In 2000, laparotomy performed for a large pelvic tumor revealed inoperable intraabdominal fibromatosis. The tumor, which was positive for estrogen and progesterone receptors, resolved during aromatase inhibitor therapy. The first follow-up computed tomographic (CT) scan revealed that the tumor masses were significantly reduced in size, and successive CT scans revealed stable disease.

Conclusion: Intraabdominal fibromatosis that expresses estrogen and progesterone receptors may respond favorably to treatment with aromatase inhibitors.

Publication types

  • Case Reports

MeSH terms

  • Aromatase Inhibitors*
  • Female
  • Fibromatosis, Abdominal / diagnostic imaging
  • Fibromatosis, Abdominal / drug therapy*
  • Fibromatosis, Abdominal / metabolism
  • Fibromatosis, Abdominal / pathology
  • Humans
  • Letrozole
  • Middle Aged
  • Nitriles / therapeutic use*
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis
  • Tomography, X-Ray Computed
  • Triazoles / therapeutic use*

Substances

  • Aromatase Inhibitors
  • Nitriles
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Triazoles
  • Letrozole